A study conducted by researchers from the Agency for Science, Technology and Research (A*STAR), National Cancer Centre Singapore (NCCS) and National University of Singapore (NUS), in collaboration with biotech company, KYAN Technologies, has demonstrated that a precision medicine approach improves treatment selection for patients with soft tissue sarcomas (STS) in a clinical setting.